Check Claims Before You Publish

Visual summary (publications & topical footprint)

Quantitative metrics & provenance

• OpenAlex / bibliometric snapshot: works_count ≈ 4, cited_by_count ≈ 21, h-index = 2; counts by year: 2023(1), 2024(1), 2025(2) (source: OpenAlex author record supplied in input).
• Selected peer-reviewed papers (representative):
  • First-author NAR 2024 — "TDP1 splice-site mutation causes HAP1 cell hypersensitivity to topoisomerase I inhibition" (Nucleic Acids Research) — open access; experimental genetics and biochemical assays; ~4 citations so far NAR 2024 — TDP1
  • Middle-author Science Advances 2023 — "RAD54L2 counters TOP2-DNA adducts to promote genome stability" — mechanistic cell biology paper with broader citations (n≈16) that addresses TOP2-DNA adduct resolution, where Goh appears in a multi-author team Sci Adv 2023 — RAD54L2
  • WEE1/GCN2 work 2025 — preprint → Nature Communications (2025) where Goh is a middle author; topic links WEE1 inhibition to translation stress via GCN2 signalling and cancer-relevant synergy biorXiv 2025 — WEE1/GCN2 preprintNat Commun 2025 — WEE1/GCN2

Critical appraisal — strengths, limitations, and blind spots

1. Strengths
   • Contribution to mechanistic, bench-focused research on DNA damage/repair and cancer-relevant signalling — papers use genetics, biochemical assays, and cell models (NAR, Sci Adv, Nat Commun) NAR 2024 — mechanistic methods
   • Presence on multi-author, high-impact team papers (Science Advances, Nature Communications) implies collaboration with established groups and exposure to rigorous experimental environments Sci Adv 2023 — team science
2. Limitations / Risks
   • Low independent output so far: only ~3–4 papers; h-index = 2 and total citations ≈18–21 indicate limited citation impact outside the team context (OpenAlex snapshot). This limits inference about independent leadership or reproducibility across diverse labs.
   • Authorship position: the strongest independent signal is the 2024 NAR first-author paper, but most high-profile work lists Goh as a middle author, so contribution magnitude varies and is not fully inferable from authorship alone Sci Adv 2023 — authorship context
   • Unknowns: institutional/independent funding, PI status, and longer-term trajectory are not present in the record; these are key to assessing potential for future independent high-impact work.
3. Potential biases & quality checks
   • Publication venues (NAR, Sci Adv, Nat Commun) implement peer review, but multi-author team papers sometimes dilute individual credit; verify contribution statements / methods for reproducibility emphasis.
   • Citation counts are low — early-career effect vs. low uptake; time lag for citations is expected for 2024–2025 work.

Conclusions & actionable recommendations

Conclusion: Goh is an early-career researcher with mechanistic bench expertise and contributions to high-quality collaborative papers; however, the small independent publication record and low citation totals limit claims about leadership or broad influence at this time (confidence: moderate).

• To strengthen scientific standing: seek (1) senior/corresponding author papers demonstrating independent hypotheses, (2) grant or fellowship awards, (3) reproducibility-focused methods/data sharing and pre-registration where possible.
• For evaluators: examine the NAR first-author paper's methods and author contribution statement to judge experimental independence; check raw data/supplementary materials for rigour.

• NAR 2024 — Goh first-author
• Sci Adv 2023 — RAD54L2
• biorXiv 2025 — WEE1 preprint
• Nat Commun 2025 — WEE1/GCN2